Objectives: Cell–cell adhesion mediated by cadherins is tight and stable and preserves tissue integrity. However, during tissue remodeling, e.g., development, adhesion may be modified for morphogenic movement. Similarly, during carcinogenesis, cell–cell adhesion might alter leading to a more aggressive phenotype. Here we describe cadherin expression patterns in developing, adult, and neoplastic kidney.
Methods: Fetal kidneys were obtained from voluntary terminations of pregnancy and 43 renal cell carcinomas (RCC) and normal kidneys were obtained at nephrectomy. Frozen sections of these specimens were stained immunohistochemically using antibodies against E–cadherin (ECD), cadherin–6 (CAD6) and α–catenin (α–cat).
Results: CAD6 was expressed in lower and middle limbs of the S–shaped bodies, structures that will develop into renal proximal tubules, which also express CAD6. Similarly, ECD was expressed in the upper limb of S–shaped bodies, structures which will develop into distal and collecting tubules which also express ECD. Twenty–four out of 43 RCC (55.8%) displayed a CAD6 (+)/ECD (–)/α–cat (+) phenotype. The other RCC had a CAD6 (+)/ECD (+)/α–cat (+) phenotype (10/43, 23.2%), CAD6 (–)/ECD (+)/α–cat (+) phenotype (3/43, 7.0%) or CAD6 (–)/ECD (–)/α–cat (+) phenotype (6/43, 14.0%), respectively. On the other hand, normal, heterogeneous, or absent expression of CAD6 was seen in 19, 15, and 9 tumors, whereas in 11, 2, and 30 tumors, respectively, ECD expression was seen. Survival curves showed that abnormal CAD6 expression correlated with a poor prognosis rather than abnormal ECD expression.
Conclusions: The combination of cadherin expression appeared to be fixed relatively early during kidney organogenesis. Since almost all RCC originate from proximal tubular epithelial cells (CAD6 (+)/ECD (–)/α–cat (+)), only 55.8% of RCC retained the original cadherin phenotype. Alterations in expression of these molecules may be a reflection of the degree of dedifferentiation from the primary organ. In addition, scoring of expression patterns including heterogeneous expression could be a useful tool to estimate the malignancy potential of the tumor.
Toru Shimazui, MD, PhD
Department of Urology, Institute of Clinical Medicine
University of Tsukuba, 1–1–1, Tennodai, Tsukuba–City
Ibaraki 305–8575 (Japan)
Tel./Fax +81 298 533223, E–Mail firstname.lastname@example.org
Accepted after revision: August 27, 1999
Number of Print Pages : 8
Number of Figures : 4, Number of Tables : 1, Number of References : 27
Official Organ of the European Association of Urology
Vol. 38, No. 3, Year 2000 (Cover Date: September 2000)
Journal Editor: C.C. Schulman, Brussels
ISSN: 0302–2838 (print), 1421–993X (Online)
For additional information: http://www.karger.ch/journals/eur
Article / Publication Details
Published online: 8/4/2000
Issue release date: September 2000
Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1
ISSN: 0302-2838 (Print)
eISSN: 1421-993X (Online)
For additional information: http://www.karger.com/EUR
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.